|67.62||+0.0500||+0.07%||Vol 422.06K||1Y Perf 43.69%|
|Apr 13th, 2021 16:00 DELAYED|
|- -||- -%|
|Target Price||66.92||Analyst Rating||Moderate Buy 1.73|
|Potential %||-1.04||Finscreener Ranking||★★+ 48.74|
|Insiders Trans % 3/6/12 mo.||-100/-100/-48||Value Ranking||★★★ 51.00|
|Insiders Value % 3/6/12 mo.||-100/-100/-99||Growth Ranking||★★★★ 62.56|
|Insiders Shares Cnt. % 3/6/12 mo.||-100/-100/-99||Income Ranking||— -|
|Market Cap||6.75B||Earnings Rating||Sell|
|Price Range Ratio 52W %||97.56||Earnings Date||6th May 2021|
Today's Price Range
5 Year PE Ratio Range
|Moving Averages:||Strong Buy|
|Earnings History||Estimate||Reported||Surprise %|
|Earnings Per End||Estimate||Revision %||Trend|
|Next Report Date||6th May 2021|
|Estimated EPS Next Report||0.36|
|EPS Growth Next 5 Years %||10.20|
|Avg. Weekly Volume||550.51K|
|Avg. Monthly Volume||480.93K|
|Avg. Quarterly Volume||465.58K|
Globus Medical Inc. Class A (NYSE: GMED) stock closed at 67.62 per share at the end of the most recent trading day (a 0.07% change compared to the prior day closing price) with a volume of 493.80K shares and market capitalization of 6.75B. Is a component of Russell 1000 indices and it is traded on NYSE exchange. The company belongs in the Medical Devices & Instruments industry, Healthcare sector and employs 2200 people. Globus Medical Inc. Class A CEO is David M. Demski.
The one-year performance of Globus Medical Inc. Class A stock is 43.69%, while year-to-date (YTD) performance is 3.68%. GMED stock has a five-year performance of 183.17%. Its 52-week range is between 42.85 and 68.24, which gives GMED stock a 52-week price range ratio of 97.56%
Globus Medical Inc. Class A currently has a PE ratio of 66.30, a price-to-book (PB) ratio of 4.39, a price-to-sale (PS) ratio of 11.27, a price to cashflow ratio of 33.70, a PEG ratio of 2.32, a ROA of 6.11%, a ROC of 6.88% and a ROE of 6.74%. The company’s profit margin is 12.72%, its EBITDA margin is 21.20%, and its revenue ttm is $598.47 Million , which makes it $6.00 revenue per share.
Of the last four earnings reports from Globus Medical Inc. Class A, there were 3 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $0.36 for the next earnings report. Globus Medical Inc. Class A’s next earnings report date is 06th May 2021.
The consensus rating of Wall Street analysts for Globus Medical Inc. Class A is Moderate Buy (1.73), with a target price of $66.92, which is -1.04% compared to the current price. The earnings rating for Globus Medical Inc. Class A stock is Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Globus Medical Inc. Class A has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Globus Medical Inc. Class A has a Buy technical analysis rating based on Technical Indicators (ADX : 6.08, ATR14 : 1.85, CCI20 : 166.73, Chaikin Money Flow : 0.34, MACD : 0.09, Money Flow Index : 81.17, ROC : 11.42, RSI : 45.99, STOCH (14,3) : 97.18, STOCH RSI : 1.00, UO : 82.78, Williams %R : -2.82), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Globus Medical Inc. Class A in the last 12-months were: Ann D. Rhoads (Sold 0 shares of value $-163 993 ), Daniel T. Scavilla (Sold 0 shares of value $-5 096 500 ), Daniel T. Scavilla (Sold 200 000 shares of value $11 018 000 ), David D. Davidar (Sold 42 000 shares of value $2 520 000 ), David M. Demski (Sold 0 shares of value $-13 631 044 ), David M. Demski (Sold 547 075 shares of value $32 544 657 ), James R. Tobin (Sold 0 shares of value $-604 210 ), James R. Tobin (Sold 23 000 shares of value $1 264 920 ), Kelly G. Huller (Sold 0 shares of value $-362 675 ), Kelly G. Huller (Sold 29 152 shares of value $1 554 492 ), Lemaitre Dan (Sold 0 shares of value $-173 532 ), Lemaitre Dan (Sold 15 384 shares of value $961 039 ), Robert Andrew Douglas (Buy at a value of $199 647)
Copyright © 2016-2021 Finscreener.org. All Rights Reserved.
Disclaimer: Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex and Tradegate data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
This could take some time, please wait.